AI
BMY.RT

Atom Investors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Atom Investors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,606,632
Closed -$3.18M – 472
2020
Q4 		$3.18M Buy
4,606,632
+3,639,872
+377% +$7.75M 0.32% 85
2020
Q3 		$2.17M Buy
+966,760
New +$2.76M 0.21% 121

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Atom Investors's BMY.RT Position: Q1 2021 in Review

Atom Investors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 4,606,632 shares — an estimated $3.18M sold.

Atom Investors first reported a position in BMY.RT in Q3 2020 and held it in 2 quarters. The position peaked at $3.18M in Q4 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Atom Investors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Atom Investors sold 4,606,632 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $3.18M.
  • Atom Investors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q3 2020 and held it in 2 quarters.
  • Atom Investors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $3.18M in Q4 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Atom Investors's 13F filing for Q1 2021, filed 17 May 2021.